粉样蛋白抑制的分子机制:用多作为案例研究的NMR驱动框架
Giacomo Zuccon1,2, Aakriti Darnal1, Edoardo Longo2
1Laimburg Research Centre, Vadena, Italy.
Frontiers in molecular biosciences
|September 29, 2025
概括
溶液状态核磁共振揭示了多如何抑制神经退行性疾病中的粉样蛋白形成. 这种方法区分了针对不同聚合阶段的抑制剂,有助于药物设计.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
背景情况:
- 蛋白质错误折叠和粉样纤维细胞的形成是神经退行性疾病的标志.
- 寡合蛋白中间体,而不仅仅是纤维,被认为是细胞毒性物种.
- 粉样蛋白抑制剂的精确机制,如多,尚未完全理解.
研究的目的:
- 探索如何溶液状态核磁共振 (NMR) 可以定量评估粉样蛋白抑制剂的机制.
- 为亨廷丁外1蛋白 (httex1) 开发一个整合早期寡合化和纤维细胞形成的动态框架.
- 模拟和区分小分子结合在蛋白质聚合的各个阶段的影响.
主要方法:
- 使用溶液态NMR光谱来监测蛋白质聚合.
- 开发一种运动模型,将可逆的寡合化与纤维细胞形成相结合.
- 应用NMR和动力学数据的全球匹配来分析抑制剂效应.
- 使用亨廷顿前列1蛋白 (httex1) 作为亨廷顿病的模型系统.
主要成果:
- 证明了单体绑定和核形成抑制产生了不同的聚合概况.
- 表明这些独特的配置文件可以使用集成的NMR和动态数据分析来解决.
- 确定NMR可以在单质,寡质或纤维状阶段区分抑制剂结合.
- 突出显示的多作为抑制剂分类的案例研究.
结论:
- 溶液状态的NMR为阐明粉样蛋白抑制机制提供了定量框架.
- 拟议的动力模型允许基于其向聚合阶段对抑制剂进行分类.
- 这种方法有助于合理设计用于神经退行性疾病的小分子抑制剂.
更多相关视频
10:15Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin
Published on: November 1, 2019
13.3K
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
14.0K
相关概念视频
03:03Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824